Correction to: “Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”
Authors: E. Kastritis, V. Leblond, M.A. Dimopoulos, E. Kimby, P. Staber, M.J. Kersten, A. Tedeschi, C. Buske
Journal: Annals of Oncology (2018)

Ann Oncol 2018; 29: v41–iv50 (doi:10.1093/annonc/mdy146) The following corrections are made: In the sections “First-line therapy (Figure 1)” and “Personalised medicine” INNOVATE Is replaced with: iNNOVATE In the section “Management, Relapsed disease” For patients who relapse > 2–3 years after receiving a rituximab-based regimen, an alternative rituximab-based combination may be considered. If rituximab with cyclophosphamide was used (i.e. DRC), rituximab with either bendamustine (i.e. BR) or bortezomib either with or without dexamethasone (i.e. BDR or VR) may be used [IV, B] [40]. Rituximab with nucleoside analogues (FR, FCR) is an active but also toxic combination and therefore should be used cautiously [III, C]. For patients who achieve a prolonged remission with their primary therapy (i.e. > 3–4 years), re-instituting the prior regimen may also be considered [IV, B] [40]. Ibrutinib may also be a treatment option for patients with late relapses. Is replaced with: For patients who relapse between 1 and 3 years, ibrutinib is an appropriate treatment choice. An alternative rituximab-based combination might be considered in patients who are not eligible for ibrutinib or who relapse later in this time period. For patients who relapse >3 years after receiving a rituximab-based regimen, an alternative rituximab-based combination may be considered. If rituximab with cyclophosphamide was used (i.e. DRC), rituximab with either bendamustine (i.e. BR) or bortezomib either with or without dexamethasone (i.e. BDR or VR) may be used [IV, B] [40]. Rituximab with nucleoside analogues (FR, FCR) is an active but also toxic combination and therefore should be used cautiously [III, C]. For patients who achieve a prolonged remission with their primary therapy (i.e. > 4 years), re-instituting the prior regimen may also be considered [IV, B] [40]. Ibrutinib may also be a treatment option for patients with late relapses. In “Figure 2. Treatment algorithm for patients with relapsed or refractory WM” The following changes apply as shown in the updated version below. Under “Fit patient” 2–3 years Is replaced with: 1–3 years Clinical trial R-based regimen (repeat or alternate) [IV, B] Ibrutinib [III, A] Is replaced with: Clinical trial Ibrutinib [III, A] Alternate R-based regimen [IV, B] Under “Unfit patient” 2–3 years Is replaced with: 1–3 years Clinical trial Alternate R-based regimen Ibrutinib [III, A] Is replaced with: Clinical trial Ibrutinib [III, A] Alternate R-based regimen [IV, B] Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 29PreviewWaldenström’s macroglobulinaemia (WM) is a rare disease that accounts for 1%–2% of non-Hodgkin lymphomas. The reported age-adjusted incidence rate is 3.4 per million among the male population and 1.7 per million among the female population in the United States, and 7.3 and 4.2 per million, respectively, in the European standard population [1, 2]. In contrast to multiple myeloma, WM prevalence is higher among Caucasians than among African-Americans (IRR: 1.75) [3]. WM is a disease of the elderly, with the median age at the time of diagnosis being 63–75 years in different series [3–5]. Full-Text PDF Open Archive